Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Bayer starts Phase III trial in non-small cell lung cancer

First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations

Royal Sense launches multiple products in pharmaceutical category

Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale

Merck receives EC approval for Winrevair for treatment of PAH

Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe

Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV

The grant is designated for the research and development of Pyronaridine

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases

Honeywell launches quality management system HQMR for Life Sciences industry

Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance

Mangalam Drugs & Organics expanding anti-malaria APl portfolio with introduction of Pyronaridine

This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability